Drug Approval | March 28, 2024
Biocon to obtain approval for diabetes drug, Liraglutide in UK
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
More than 10,000 scientific publications containing EUDRAGIT
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
It is the first autotaxin inhibitor to be investigated in cancer patients
These approvals mark significant progress for Venus Remedies in expanding its market presence
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
Acquisition of exclusive commercialization rights for European markets
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
Subscribe To Our Newsletter & Stay Updated
